In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Did you know that your browser is out of date? To get the best experience using our website we recommend that you upgrade to a newer version. Learn more.
COVID-19 and Cardiology Read more

Antithrombotic Therapies 2019: clinical challenges and future directions

Joint Educational Training Programme of the ESC Working Group on Aorta & Peripheral Vascular Diseases and the ESC Working Group on Thrombosis

A rich training program featuring four main areas addressed from both Working Groups’ perspective:

  1. Interactions between endothelium and primary/secondary haemostasis;
  2. Antithrombotic in special populations (including diabetes, obesity, elderly and frailty, pregnancy);
  3. Combined antithrombotic strategies in Atherothrombotic diseases (stable versus unstable, AF, PAD, short and long term);
  4. Treatment and secondary prevention of Venous thromboembolism (in the general population and in cancer patients).

Webcasts


 

Learning objectives

The Educational Training Programme is composed of 8 sessions aiming at:

  • Understanding clinically-relevant mechanisms of action (haemostatic and pharmacological) underlying the most recent and effective combined antithrombotic strategies in atherothrombotic and venous thromboembolic diseases;
  • Managing atherothrombotic diseases in the chronic and acute settings, in special patient populations such as diabetic, chronic kidney disease, pregnant, obese, older and/or frail patients who remain an unmet clinical need in spite of the most recent evidence;
  • Managing cardioembolic and venous thromboembolic diseases in the chronic and/or acute settings, with a special focus on cancer patients.

Programme

Faculty members list:

Working Group on Aorta & Peripheral Vascular Diseases (WGA-PVD)

  1. Victor Aboyans- Chair
  2. Marco De Carlo- Past Chair
  3. Lucia Mazzolai- Vice Chair
  4. Oliver Schlager- Treasurer
  5. Marianne Brodmann
  6. Christine Espinola-Klein
  7. José Rodriguez-Palomares
  8. Emmanuel Messas
  9. Dimitrios Terentes-Printzios

Working Group on Thrombosis (WGT)

  1. Dirk Sibbing- Chair
  2. Bianca Rocca- Past Chair
  3. Gemma Vilahur- Vice Chair
  4. Andrea Rubboli- Treasurer
  5. Diana Gorog
  6. Rob Storey
  7. Jean Philippe Collet
  8. Joao Morais
  9. Tobias Geisler

Special Guest: Lars Wallentin

Wednesday 12 June

13:00-14:30: Registration and lunch

14:30-14:50: Welcome message from the Working Groups Chairpersons - V Aboyans and D Sibbing

14:50-16:20: Session 1

Focus on the pathophysiology of endothelium and haemostasis / thrombosis

Chairs: V Aboyans and D Sibbing

  1. Platelets and atherothrombosis - B Rocca
  2. Endothelial function and biomarkers in PAD - D Terentes-Printzios
  3. Factor Xa: a crossroad between coagulation and platelet - T Geisler
  4. Novel targets in the coagulation pathway - D Gorog

16:20-16:45: Networking

16.45-18.15: Session 2

Antithombotic strategies in peripheral arteries

Chairs: M Brodmann and O Schlager

  1. Antithrombotic strategies in carotid artery disease. Lucia Mazzolai
  2. Dual antithrombotic therapies in stable patients with PAD. C Espinola-Klein
  3. DAPT after peripheral revascularization. M De Carlo
  4. AF & PAD: a non-random association. V Aboyans

18.30-19.00: Lecture

Antithrombotic therapies: how to assess bleeding risk and its severity?

Chairs: V Aboyans and D Sibbing

Lecturer: Lars Wallentin

19.00-20.30: Networking cocktail at the Heart House

Thursday 13 June

Morning sessions

09:00-10:30: Session 1

Combined antithrombotic strategies in CAD

Chairs: D Sibbing and T Geisler

  1. Update on DAPT in the first year after ACS - R Storey
  2. Dual antithrombotic strategy in stable CAD: for whom? - D Sibbing
  3. Antithrombotic and antiplatelet agents one-year post-MI: how many options? - T Geisler
  4. Atrial Fibrillation in stable CAD and ACS - A Rubboli

10:30-11:00: Networking

11:00-12:30: Session 2

Antithrombotic therapies in special populations

Chairs: D Gorog and M De Carlo

  1. Antithrombotic therapies in acquired and congenital thrombophilic disorders? - L Mazzolai
  2. Antithrombotic therapies in pregnancy - M Brodmann
  3. Antithrombotic therapies in CKD - D Gorog
  4. Antithrombotic therapies in the old/frail patients - E. Messas

12:30-14:00: Lunch and networking

Afternoon sessions

14:00-15:30: Session 1

Antithrombotic therapies and diabetes and/or metabolic syndrome

Chairs: J Rodriguez-Palomares and B Rocca

The haemostatic imbalance in type 2 diabetes and Metabolic Syndrome - G Vilahur Garcia
Antithrombotic strategies in diabetic patients with CAD - M De Carlo
Antithrombotic strategies in diabetic patients with PAD - C Espinola-Klein
Obesity and antithrombotic strategies in arterial and venous diseases - R Storey

15.30-16:00: Networking

16:00-17:30: Session 2

Focus on venous thromboembolism

Chairs: A Rubboli and E Messas

  • Prevention of VTE: when and how? Joao Morais
  • PE, DVT and SVT: current management. M Brodmann
  • Long-term anticoagulation after PE/DVT: when and how? C Espinola-Klein
  • Prevention and treatment of post-thrombotic syndrome. O Schlager

17:30-18:00: Networking

18:00-18:40: Debate Session

Antithrombotic strategies in asymptomatic patients: Pros and Cons

Chairs: J Morais and D Terentes-Printzios

  1. Antithrombotic therapy is indicated in Primary Prevention (pro) - B Rocca
  2. Antithrombotic therapy is indicated in Primary Prevention (contra) - V Aboyans
  3. Rebuttal - B Rocca
  4. Rebuttal - V Aboyans

18:40: Wrap up

Friday 14 June

09:00-10:30: Session 1

Focus on venous thromboembolism and cancer

20 min +10 common discussion at the end

Chairs: C Espinola-Klein and G Vilahur Garcia

  1. Haemostasis and thrombosis in cancer - G Vilahur Garcia
  2. Coronary and stroke events in patients with cancer - J Morais
  3. Management of VTE in patients with cancer - O Schlager
  4. Looking for cancer after VTE? When and how? - E. Messas

10:30-10:45: Networking

10:45-12:15: Session 2

Antithrombotic therapies and cardiovascular devices

20 min +10 common discussion at the end

Chairs: T Geisler and D Terentes-Printzios

  1. PFO closure: indications and antithrombotic strategy after implantation - JP Collet
  2. Left atrial appendage occlusion: indications and antithrombotic strategy thereafter - A Rubboli
  3. TAVI, SAVI and antithrombotic strategies thereafter - D Sibbing
  4. Aortic diseases, TEVAR, EVAR and antithrombotic strategies - J Rodriguez-Palomares

12:15-12:30: Closing remarks - V Aboyans and G Vilahur Garcia